<DOC>
	<DOC>NCT00695539</DOC>
	<brief_summary>This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek subjects with hypercholesterolemia under normal clinical practice.</brief_summary>
	<brief_title>Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients with hypercholesterolaemia who are already in treatment with rosuvastatin according to the approved SPC for no longer than 1 month prior to study entry Patients that are able to read, understand and sign the Patient Information &amp; Consent Form Patients that are willing to comply with all study requirements Patients that are likely not to comply with all study requirements Patients that currently participate or have participated in a 3 months period prior to study entry in another clinical trial Female of child bearing potential that do not use a reliable method of contraception. Pregnancy or lactation. Patients that meet any of the contraindications described in the approved SPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Rosuvastatin</keyword>
	<keyword>hypercholesterolaemia</keyword>
</DOC>